Price | 1W % | 1M % | 3M % | 6M % | 1Y % | YTD % |
|---|---|---|---|---|---|---|
-- | -- | -- | -- | -- | -- | -- |
AI Generated Qualitative Analysis
Your time is precious, so save it. Use AI to get the most important information from the business.
Learn about Olema Pharmaceuticals, Inc.
Olema Pharmaceuticals, Inc. News
Olema Pharmaceuticals, Inc. Quantitative Score
About Olema Pharmaceuticals, Inc.
Olema Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies for women's cancers. Its lead product candidate is OP-1250, an estrogen receptor (ER) antagonist and a selective ER degrader, which is in Phase 1/2 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive, human epidermal growth factor receptor 2-negative breast cancer. The company was formerly known as CombiThera, Inc. and changed its name to Olema Pharmaceuticals, Inc. in March 2009. Olema Pharmaceuticals, Inc. was incorporated in 2006 and is headquartered in San Francisco, California.
Olema Pharmaceuticals, Inc. Earnings & Revenue
What’s This Company Really Worth? Find Out Instantly.
Warren Buffett’s go-to valuation method is Discounted Cash Flow (DCF). Our tool makes it effortless — no spreadsheets, just answers in a few clicks.
Olema Pharmaceuticals, Inc. Financials
Table Compare
Compare OLMA metrics with: | |||
|---|---|---|---|
Earnings & Growth | OLMA | None | |
EPS (TTM) YoY Growth | -- | -- | |
Revenue (TTM) YoY Growth | -- | -- | |
Valuation (TTM) | OLMA | None | |
Price/Earnings Ratio | -- | -- | |
Price/Sales Ratio | -- | -- | |
Profitability & Efficiency (TTM) | OLMA | None | |
Net Profit Margin | -- | -- | |
Return on Equity | -- | -- | |
Financial Health (TTM) | OLMA | None | |
Debt/Assets Ratio | -- | -- | |
Assets/Liabilities Ratio | -- | -- | |
Olema Pharmaceuticals, Inc. Income
Olema Pharmaceuticals, Inc. Balance Sheet
Olema Pharmaceuticals, Inc. Cash Flow
Olema Pharmaceuticals, Inc. Financials Over Time
Analysts Rating
Strong Buy
Buy
Hold
Sell
Strong Sell
Metrics Scores
| Metrics | Score |
|---|---|
| Discounted Cash Flows | Neutral |
| Return on Equity | Strong Sell |
| Return on Assets | Strong Sell |
| Debt/Equity Ratio | Buy |
| Price/Earnings Ratio | Strong Sell |
| Price/Book Ratio | Neutral |
Price Targets
Disclaimer: This 3rd party analysis information is for reference only and does not constitute investment advice.
Historical Market Cap
Shares Outstanding
Olema Pharmaceuticals, Inc. Executives
| Name | Role |
|---|---|
| Sean Bohen | President, Chief Executive Officer & Director |
| Shane William Charles Kovacs | Chief Operating & Financial Officer |
| Naseem Zojwalla | Chief Medical Officer |
| David C. Myles | Chief Discovery & Non-Clinical Development Officer |
| Kamesh Kuchimanchi | Senior Vice President of Regulatory Affairs & Quality Assurance |
| Name | Role | Gender | Date of Birth | Pay |
|---|---|---|---|---|
| Sean Bohen | President, Chief Executive Officer & Director | 1967 | 1.12M | |
| Shane William Charles Kovacs | Chief Operating & Financial Officer | Male | 1974 | 845.37K |
| Naseem Zojwalla | Chief Medical Officer | 1973 | 777.97K | |
| David C. Myles | Chief Discovery & Non-Clinical Development Officer | 1963 | 200K | |
| Kamesh Kuchimanchi | Senior Vice President of Regulatory Affairs & Quality Assurance | -- |
Olema Pharmaceuticals, Inc. Insider Trades
| Date | 26 Dec |
| Name | Bohen Sean |
| Role | President and CEO |
| Transaction | Disposed |
| Type | G-Gift |
| Shares | 8500 |
| Date | 22 Dec |
| Name | Harmon Cyrus |
| Role | Director |
| Transaction | Disposed |
| Type | S-Sale |
| Shares | 2881 |
| Date | 19 Dec |
| Name | CLARK IAN T |
| Role | Director |
| Transaction | Acquired |
| Type | M-Exempt |
| Shares | 209690 |
| Date | 19 Dec |
| Name | CLARK IAN T |
| Role | Director |
| Transaction | Acquired |
| Type | M-Exempt |
| Shares | 21520 |
| Date | 19 Dec |
| Name | CLARK IAN T |
| Role | Director |
| Transaction | Acquired |
| Type | M-Exempt |
| Shares | 21520 |
| Date | Name | Role | Transaction | Type | Shares |
|---|---|---|---|---|---|
| 26 Dec | Bohen Sean | President and CEO | Disposed | G-Gift | 8500 |
| 22 Dec | Harmon Cyrus | Director | Disposed | S-Sale | 2881 |
| 19 Dec | CLARK IAN T | Director | Acquired | M-Exempt | 209690 |
| 19 Dec | CLARK IAN T | Director | Acquired | M-Exempt | 21520 |
| 19 Dec | CLARK IAN T | Director | Acquired | M-Exempt | 21520 |